EX-99.4 5 exh_994.htm EXHIBIT 99.4

Exhibit 99.4

 

Third Amendment

 

This Amendment (the "Third Amendment") effective as of May 19, 2016 (the "Effective Date"), is entered into by and between CRYSTALGENOMICS, INC., a South Korean corporation having a place of business at 5th F. Bldg.A, Korea Bio Park, 700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-400 Korea ("CG") and APTOSE BIOSCIENCES, INC., a Canadian corporation having a place of business at 5955 Airport Road, Suite 228, Mississauga, Ontario, L4V 1R9, Canada ("Aptose"). CG and Aptose are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

 

The Parties hereby desire to make an amendment of the OPTION AND LICENSE AGREEMENT (the "Agreement") between CG and Aptose with an Execution Date of March 24, 2016 to revise the following terms and conditions per below, pursuant to Section 2.1 of the Agreement.

 

1.The Parties agree to extend the Evaluation Period until June 6, 2016.
   
 2.Upon Aptose's decision to obtain the option on or before June 6, 2016, Aptose shall pay CG, as evidenced by a wire transfer receipt, the Option Grant Fee by the end of business, 5pm US Eastern Standard Time (EST), June 6, 2016.

 

This Third Amendment hereby replaces the First Amendment, which was executed on April 26, 2016.

 

IN WITNESS WHEREOF, the parties hereto have caused this Third Amendment to be executed as of the Effective Date written above by their respective authorized representatives. The parties hereby affirm that this Third Amendment accurately and completely reflects their understanding and agreements.

 

 

CRYSTALGENOMICS, INC.   APTOSE BIOSCIENCES, INC.
     
     
By:

/s/ Dr. Joong Myung Cho

  By:

/s/ Avanish Vellanki

         
Name:

Dr. Joong Myung Cho

  Name:

Avanish Vellanki

         
Title:

CEO

  Title:

SVP, Chief Business Officer

         
Date:

May 19, 2016

  Date:

May 19, 2016